{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:39Z","timestamp":1789469139253,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoimmune hemolytic anemia (AIHA) is associated with a significant impairment of quality of life for affected patients and can lead to life-threating hemolytic crises. Complement-mediated destruction of antibody-opsonized erythrocytes is a central pathomechanism in many cases of AIHA. Complement inhibition is therefore a promising and logical therapeutic strategy. Sutimlimab, a monoclonal antibody that targets complement factor C1s was approved in 2022 and can effectively inhibit hemolysis. However, this therapy must be administered as a permanent treatment and is only approved for the specific subtype cold agglutinin disease. In this case series, we report on a novel combination therapy of sutimlimab and rituximab, which led to rapid and durable remission in three patients suffering from severe autoimmune hemolytic anemia (two patients with cold agglutinin syndrome and one patient with primary warm AIHA). In two of these patients, treatment with sutimlimab could be discontinued without any recurrence to date. The other patient is also in remission but with ongoing therapy. This highly informative case series reports on an innovative therapeutic concept and may form the basis for further clinical studies in AIHA.<\/jats:p>","DOI":"10.1007\/s00277-026-07231-6","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:22:34Z","timestamp":1787048554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy of sutimlimab and rituximab can lead to stable remission in autoimmune hemolytic anemia: a case series"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6944-3752","authenticated-orcid":false,"given":"Julian","family":"List","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kutilina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Duque-Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"15","key":"7231_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMra2033982","volume":"385","author":"S Berentsen","year":"2021","unstructured":"Berentsen S, Barcellini W (2021) Autoimmune Hemolytic Anemias. N Engl J Med 385(15):1407\u20131419. https:\/\/doi.org\/10.1056\/NEJMra2033982","journal-title":"N Engl J Med"},{"issue":"7","key":"7231_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/17474086.2024.2366540","volume":"17","author":"W Barcellini","year":"2024","unstructured":"Barcellini W, Fattizzo B (2024) The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease. Expert Rev Hematol 17(7):287\u2013294. https:\/\/doi.org\/10.1080\/17474086.2024.2366540","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"7231_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/1744666x.2022.2089115","volume":"18","author":"B Fattizzo","year":"2022","unstructured":"Fattizzo B, Barcellini W (2022) Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol 18(7):731\u2013745. https:\/\/doi.org\/10.1080\/1744666x.2022.2089115","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"7231_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000438964","volume":"42","author":"S Berentsen","year":"2015","unstructured":"Berentsen S (2015) Role of Complement in Autoimmune Hemolytic Anemia. Transfus Med Hemother 42(5):303\u2013310. https:\/\/doi.org\/10.1159\/000438964","journal-title":"Transfus Med Hemother"},{"issue":"10","key":"7231_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","volume":"99","author":"A Zanella","year":"2014","unstructured":"Zanella A, Barcellini W (2014) Treatment of autoimmune hemolytic anemias. Haematologica 99(10):1547\u20131554. https:\/\/doi.org\/10.3324\/haematol.2014.114561","journal-title":"Haematologica"},{"issue":"4","key":"7231_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","volume":"130","author":"S Berentsen","year":"2017","unstructured":"Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Hauk\u00e5s E, Brudevold R, S\u00f8rb\u00f8 JH, N\u00e6ss IA, Malecka A, Tj\u00f8nnfjord GE (2017) Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 130(4):537\u2013541. https:\/\/doi.org\/10.1182\/blood-2017-04-778175","journal-title":"Blood"},{"issue":"19","key":"7231_CR7","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","volume":"2","author":"A R\u00f6th","year":"2018","unstructured":"R\u00f6th A, Bommer M, H\u00fcttmann A, Herich-Terh\u00fcrne D, Kuklik N, Rekowski J, Lenz V, Schrezenmeier H, D\u00fchrsen U (2018) Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv 2(19):2543\u20132549. https:\/\/doi.org\/10.1182\/bloodadvances.2018024190","journal-title":"Blood Adv"},{"key":"7231_CR8","doi-asserted-by":"publisher","unstructured":"Murakhovskaya I (2020) Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 9(12). https:\/\/doi.org\/10.3390\/jcm9124034","DOI":"10.3390\/jcm9124034"},{"issue":"1","key":"7231_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ejh.13764","volume":"109","author":"DL Hansen","year":"2022","unstructured":"Hansen DL, M\u00f6ller S, Frederiksen H (2022) Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up. Eur J Haematol 109(1):10\u201320. https:\/\/doi.org\/10.1111\/ejh.13764","journal-title":"Eur J Haematol"},{"issue":"9","key":"7231_CR10","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood.2021014955","volume":"140","author":"A R\u00f6th","year":"2022","unstructured":"R\u00f6th A, Berentsen S, Barcellini W, D\u2019Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Ward\u0119cki M, Shafer F, Lee M, Broome CM (2022) Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood 140(9):980\u2013991. https:\/\/doi.org\/10.1182\/blood.2021014955","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07231-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07231-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07231-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:51Z","timestamp":1789465371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07231-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7231"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07231-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethic declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written consent for the publication of their cases.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JL reports travel support from Recordati and Incyte, AKF reports Travel support from BeOne Medicines, JD-A reports speaker honoraria and consulting fees from AbbVie, Amgen, AstraZeneca, BeiGene, IPSEN, Lilly, Novo Nordisk, Riemser, Roche, and SOBI; and reports travel support from BeiGene, Gilead, IPSEN, Lilly, Roche, and SOBI. RM reports travel support and speaker honoraria from Recordati.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"384"}}